| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.81 [0.70, 0.94] | | < 1 | | 0% | 4 studies (4/-) | 99.7 % | some concern | not evaluable | moderate | crucial | - |
| progression or deaths (PFS) | 0.62 [0.49, 0.77] | | < 1 | | 61% | 4 studies (4/-) | 100.0 % | some concern | not evaluable | moderate | important | - |
| DOR | 0.41 [0.20, 0.83] | | < 1 | | 0% | 1 study (1/-) | 99.3 % | NA | not evaluable | | non important | - |
| objective responses (ORR) | 2.47 [0.82, 7.40] | | > 1 | | 91% | 4 studies (4/-) | 94.6 % | low | not evaluable | high | non important | - |
safety endpoints 00 |
| AE (any grade) | 2.03 [0.18, 23.06] | | < 1 | | 0% | 1 study (1/-) | 28.5 % | NA | not evaluable | | non important | - |
| AE (grade 3-4) | 2.44 [1.17, 5.12] | | < 1 | | 0% | 1 study (1/-) | 0.9 % | NA | not evaluable | | non important | - |
| AE leading to death (grade 5) | 1.39 [0.51, 3.81] | | < 1 | | 0% | 2 studies (2/-) | 26.0 % | low | not evaluable | high | non important | - |
| AE leading to treatment discontinuation (any grade) | 1.36 [0.42, 4.40] | | < 1 | | 84% | 2 studies (2/-) | 30.5 % | low | not evaluable | high | non important | - |
| STRAE (any grade) | 1.24 [0.85, 1.81] | | < 1 | | 0% | 1 study (1/-) | 12.9 % | NA | not evaluable | | non important | - |
| TRAE (any grade) | 0.68 [0.48, 0.96] | | < 1 | | 0% | 4 studies (4/-) | 98.7 % | some concern | not evaluable | moderate | non important | - |
| TRAE (grade 3-4) | 1.02 [0.45, 2.30] | | < 1 | | 89% | 4 studies (4/-) | 48.5 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to death (grade 5) | 1.62 [0.21, 12.60] | | < 1 | | 0% | 3 studies (3/-) | 32.4 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to discontinuation (any grade) | 1.62 [0.86, 3.05] | | < 1 | | 36% | 3 studies (3/-) | 6.8 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to discontinuation (grade 3-4) | 2.06 [0.87, 4.87] | | < 1 | | 0% | 2 studies (2/-) | 5.1 % | some concern | not evaluable | moderate | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Alopecia TRAE (grade 3-4) | 0.96 [0.06, 15.38] | | < 1 | | 0% | 2 studies (2/-) | 51.2 % | some concern | not evaluable | moderate | non important | - |
| Anaemia TRAE (grade 3-4) | 0.08 [0.01, 0.43] | | < 1 | | 0% | 2 studies (2/-) | 99.8 % | some concern | not evaluable | moderate | non important | - |
| Arthralgia TRAE (grade 3-4) | 1.30 [0.50, 3.42] | | < 1 | | 0% | 3 studies (3/-) | 29.4 % | low | not evaluable | high | non important | - |
| Asthenia TRAE (grade 3-4) | 1.64 [0.45, 5.96] | | < 1 | | 0% | 3 studies (3/-) | 22.5 % | low | not evaluable | high | non important | - |
| Blood creatinine increased TRAE (grade 3-4) | 0.61 [0.02, 18.27] | | < 1 | | 0% | 1 study (1/-) | 61.1 % | NA | not evaluable | | non important | - |
| Chorioretinopathy TRAE (grade 3-4) | 0.61 [0.02, 18.27] | | < 1 | | 0% | 1 study (1/-) | 61.1 % | NA | not evaluable | | non important | - |
| Colitis TRAE (grade 3-4) | 1.66 [0.25, 11.00] | | < 1 | | 0% | 2 studies (2/-) | 30.0 % | some concern | not evaluable | moderate | non important | - |
| Constipation TRAE (grade 3-4) | 0.96 [0.06, 15.38] | | < 1 | | 0% | 2 studies (2/-) | 51.2 % | some concern | not evaluable | moderate | non important | - |
| Decreased appetite TRAE (grade 3-4) | 0.58 [0.07, 4.55] | | < 1 | | 0% | 3 studies (3/-) | 69.9 % | some concern | not evaluable | moderate | non important | - |
| Diarrhoea TRAE (grade 3-4) | 0.65 [0.27, 1.59] | | < 1 | | 0% | 3 studies (3/-) | 82.7 % | low | not evaluable | high | non important | - |
| Dry skin TRAE (grade 3-4) | 1.98 [0.25, 15.69] | | < 1 | | 0% | 3 studies (3/-) | 26.0 % | some concern | not evaluable | moderate | non important | - |
| Erythema TRAE (grade 3-4) | 7.41 [0.37, 148.78] | | < 1 | | 0% | 1 study (1/-) | 9.8 % | NA | not evaluable | | non important | - |
| Fatigue TRAE (grade 3-4) | 0.48 [0.10, 2.26] | | < 1 | | 57% | 3 studies (3/-) | 82.4 % | some concern | not evaluable | moderate | non important | - |
| Hepatitis TRAE (grade 3-4) | 2.26 [0.20, 25.79] | | < 1 | | 0% | 2 studies (2/-) | 25.8 % | some concern | not evaluable | moderate | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 1.98 [0.25, 15.69] | | < 1 | | 0% | 3 studies (3/-) | 26.0 % | some concern | not evaluable | moderate | non important | - |
| Hypophysitis TRAE (grade 3-4) | 1.43 [0.11, 18.64] | | < 1 | | 0% | 2 studies (2/-) | 39.4 % | some concern | not evaluable | moderate | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 0.96 [0.06, 15.38] | | < 1 | | 0% | 2 studies (2/-) | 51.2 % | some concern | not evaluable | moderate | non important | - |
| Increased lipase level TRAE (grade 3-4) | 0.99 [0.64, 1.52] | | < 1 | | 0% | 1 study (1/-) | 52.3 % | NA | not evaluable | | non important | - |
| Leucopenia TRAE (grade 3-4) | 0.07 [0.01, 0.50] | | < 1 | | 0% | 2 studies (2/-) | 99.5 % | some concern | not evaluable | moderate | non important | - |
| Maculopapular rash TRAE (grade 3-4) | 1.38 [0.80, 2.37] | | < 1 | | 0% | 3 studies (3/-) | 12.1 % | low | not evaluable | high | non important | - |
| Myalgia TRAE (grade 3-4) | 1.61 [0.35, 7.36] | | < 1 | | 0% | 3 studies (3/-) | 27.2 % | some concern | not evaluable | moderate | non important | - |
| Nausea TRAE (grade 3-4) | 0.18 [0.05, 0.69] | | < 1 | | 0% | 3 studies (3/-) | 99.4 % | some concern | not evaluable | moderate | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.08 [0.01, 0.60] | | < 1 | | 0% | 2 studies (2/-) | 99.3 % | some concern | not evaluable | moderate | non important | - |
| Pancreatitis TRAE (grade 3-4) | 1.42 [0.11, 18.63] | | < 1 | | 0% | 2 studies (2/-) | 39.4 % | some concern | not evaluable | moderate | non important | - |
| Paraesthesia TRAE (grade 3-4) | 0.96 [0.06, 15.38] | | < 1 | | 0% | 2 studies (2/-) | 51.2 % | some concern | not evaluable | moderate | non important | - |
| Peripheral neuropathy TRAE (grade 3-4) | 0.24 [0.03, 2.13] | | < 1 | | 0% | 2 studies (2/-) | 89.9 % | some concern | not evaluable | moderate | non important | - |
| Peripheral oedema TRAE (grade 3-4) | 1.22 [0.02, 61.84] | | < 1 | | 0% | 1 study (1/-) | 46.1 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 4.00 [0.65, 24.72] | | < 1 | | 0% | 3 studies (3/-) | 6.9 % | some concern | not evaluable | moderate | non important | - |
| Pruritus TRAE (grade 3-4) | 1.64 [0.27, 10.10] | | < 1 | | 0% | 3 studies (3/-) | 29.8 % | low | not evaluable | high | non important | - |
| Pyrexia TRAE (grade 3-4) | 1.22 [0.24, 6.13] | | < 1 | | 0% | 1 study (1/-) | 40.3 % | NA | not evaluable | | non important | - |
| Rash TRAE (grade 3-4) | 0.97 [0.53, 1.78] | | < 1 | | 0% | 3 studies (3/-) | 53.4 % | low | not evaluable | high | non important | - |
| Thrombocytopenia TRAE (grade 3-4) | 0.18 [0.03, 1.07] | | < 1 | | 0% | 2 studies (2/-) | 97.0 % | some concern | not evaluable | moderate | non important | - |
| Uveitis TRAE (grade 3-4) | 1.42 [0.11, 18.63] | | < 1 | | 0% | 2 studies (2/-) | 39.4 % | some concern | not evaluable | moderate | non important | - |
| Vitiligo TRAE (grade 3-4) | 0.96 [0.06, 15.38] | | < 1 | | 0% | 2 studies (2/-) | 51.2 % | some concern | not evaluable | moderate | non important | - |
| Vomiting TRAE (grade 3-4) | 0.33 [0.11, 1.03] | | < 1 | | 0% | 3 studies (3/-) | 97.2 % | some concern | not evaluable | moderate | non important | - |
AE (grade 3-4) endpoints 00 |
| Hypothyroidism AE (grade 3-4) | 1.22 [0.02, 61.84] | | < 1 | | 0% | 1 study (1/-) | 46.1 % | NA | not evaluable | | non important | - |
